GlobeNewswire

Percona Live Open Source Database Conference Europe 2017 Showcases Power, Popularity and Innovation of Open Source Database-Powered Infrastructures

Dela

Call for Papers Coming Soon for Percona Live Open Source Database Conference 2018, April 23-25, Santa Clara, Calif.

RALEIGH, N.C., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MongoDB® and other open source database solutions and services, announced the success of Percona Live Open Source Database Conference Europe 2017, which took place September 25-27, 2017 at the Radisson Blu Royal Hotel in Dublin, Ireland.

The Percona Live Open Source Database Conference Europe is the premier event for individuals and businesses developing and using open source software. The conference theme this year was "Championing Open Source Databases," and the event included more than 100 speakers sharing their in-depth knowledge with more than 350 attendees.

"This year's Percona Live Open Source Database Conference Europe demonstrated how open source database solutions are powering digital transformation and enabling organizations of all sizes and across all industries to innovate and grow rapidly," said Peter Zaitsev, co-founder and CEO of Percona. "Once again, I want to thank all our champions of open source databases - our sponsors, speakers and attendees - for taking time to share their knowledge and insights to create an inspiring environment of learning and community."

Keynote Addresses and Breakout Sessions
This year's Percona Live Open Source Database Conference Europe featured 11 keynote addresses (available on YouTube) and more than 100 informative tutorials and breakout sessions, including:

  • Championing Open Source Databases - Peter Zaitsev, Percona
  • MySQL as a Layered Service: How to Use ProxySQL to Control Traffic and Scale Out - Rene Cannao, ProxySQL
  • Real Time DNS Analytics at Cloudflare with ClickHouse - Tom Arnfeld, Cloudflare
  • Why Open Sourcing Our Database Tooling Was the Smart Decision - Shlomi Noach, GitHub
  • MyRocks at Facebook and a Roadmap - Yoshinori Matsunobu, Facebook
  • Prometheus for Monitoring Metrics - Brian Brazil, Prometheus/Robust Perception
  • State of the Dolphin - Geir Høydalsvik, Oracle
  • Many Faces of Continuent Tungsten - MC Brown, Continuent
  • Database Performance in High Traffic Environments - Pavel Genov, Pepper
  • MySQL 8.0: Atomic DDLs - Implementation and Impact - Ståle Deraas, Oracle
  • RocksDB Static Sorted Table (SST) Formats: Considerations When Building a Search Engine - Tarek Sheasha, Booking.com
  • High Performance JSON - PostgreSQL vs. MongoDB - Wei Shan Ang and Dominic Dwyer, GlobalSign
  • Automating and Managing MongoDB: An Analysis of Ops Manager vs. ClusterControl - Ruairí Newman, Severalnines AB
  • Building Multi-Petabyte Data Warehouses with  ClickHouse - Alexander Zaitsev, LifeStreet/Altinity
  • Scaling and Hardware Provisioning for Databases: Lessons Learned at Wikipedia - Jaime Crespo, Wikimedia Foundation

Sponsorships
Percona Live Open Source Database Conference Europe 2017 was made possible through the support of the following sponsors:

  • Diamond Sponsor - Continuent
  • Gold Sponsors - Facebook, VividCortex
  • Exhibitor Sponsors - Altinity, Ispirer, PGDAY Russia '17, Rackspace, Severalnines, TimescaleDB
  • Contributor Sponsors - Webyog, Oracle MySQL
  • Media Sponsors - CMSWire, Datanami, InsideBigData, InsideHPC, ODBMS.org, Opensource.com, O'Reilly Media

The Next Percona Live Conference

What: Percona Live Open Source Database Conference 2018 
Where: Santa Clara, Calif. 
When: April 23-25, 2018

The call for papers for Percona Live Open Source Database Conference 2018 will be opened soon, look to the conference landing page for news and updates.

Company Information

Press Contact
Brigit Valencia
For Percona
(360) 597-4516
bdbvalencia@gmail.com

About Percona

With more than 3,000 customers worldwide, Percona is the only company that delivers enterprise-class solutions for both MySQL®, MongoDB® and other open source databases across traditional and cloud-based platforms. The company provides SoftwareSupport,  Consulting, and Managed Services to large, well-known global brands such as Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway and the BBC, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. Well established as thought leaders, Percona experts author content for the Percona Database Performance Blog and the Percona Live Open Source Database Conferences draw attendees and expert technical speakers from around the world. For more information, visit www.percona.com.

Percona®, XtraBackup®, TokuDB® and Fractal Tree® are registered trademarks of Percona LLC or its subsidiaries. All other registered and unregistered trademarks in this document are the sole property of their respective owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Percona via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum